Monte Rosa Therapeutics, Inc. (GLUE) Financial Statements
Monte Rosa Therapeutics, Inc. (GLUE) reported trailing twelve-month revenue of $28.7M (down 83.9% year on year) and net income of -$161.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$32.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GLUEMonte Rosa Therapeutics, Inc.Follow GLUE — free
—
Price chart with a free account
- Market cap
- 924.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Revenue | 75.6 | 123.7 | 28.7 | |
| Research & development | 121.6 | 141.5 | 170.7 | |
| Operating income | -81.1 | -54.2 | -181.9 | |
| Pre-tax income | -70.1 | -39.7 | -164.0 | |
| Income tax | 2.6 | -1.1 | -2.9 | |
| Net income | -72.7 | -38.6 | -161.1 | |
| Diluted EPS ($) | -0.98 | -0.46 | -1.59 | |
| Diluted shares (mn) | 73.9 | 83.1 | — |
USD millions · SEC XBRL
Monte Rosa Therapeutics, Inc. — questions
- What is Monte Rosa Therapeutics, Inc.'s revenue?
- $28.7M over the twelve months to 2026-06-30, down 83.9% year on year, from its 10-Q and 10-K filings.
- What is Monte Rosa Therapeutics, Inc.'s net income?
- -$161.1M over the twelve months to 2026-06-30.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- -$32.1M over the twelve months to 2026-06-30.
- What are Monte Rosa Therapeutics, Inc.'s diluted earnings per share?
- $-1.59 over the twelve months to 2026-06-30.
Every figure on this page comes from Monte Rosa Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.